IS5246A - Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum - Google Patents

Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum

Info

Publication number
IS5246A
IS5246A IS5246A IS5246A IS5246A IS 5246 A IS5246 A IS 5246A IS 5246 A IS5246 A IS 5246A IS 5246 A IS5246 A IS 5246A IS 5246 A IS5246 A IS 5246A
Authority
IS
Iceland
Prior art keywords
hemisulfate
nucleated
carbocyclic
treatment
viral infections
Prior art date
Application number
IS5246A
Other languages
English (en)
Other versions
IS2207B (is
Inventor
Couper Brodie Alastair
Francis Jones Martin
Frederick Seager John
John Wallis Christopher
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10812407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5246A publication Critical patent/IS5246A/is
Publication of IS2207B publication Critical patent/IS2207B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
IS5246A 1997-05-17 1999-11-11 Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum IS2207B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
PCT/EP1998/002835 WO1998052949A1 (en) 1997-05-17 1998-05-14 Carbocyclic nucleoside hemisulfate and its use in treating viral infections

Publications (2)

Publication Number Publication Date
IS5246A true IS5246A (is) 1999-11-11
IS2207B IS2207B (is) 2007-02-15

Family

ID=10812407

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5246A IS2207B (is) 1997-05-17 1999-11-11 Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum

Country Status (51)

Country Link
US (1) US6294540B1 (is)
EP (1) EP0983271B1 (is)
JP (2) JP3150711B2 (is)
KR (1) KR100521292B1 (is)
CN (2) CN100408580C (is)
AP (1) AP2009A (is)
AR (2) AR015668A1 (is)
AT (1) ATE259811T1 (is)
AU (1) AU739953B2 (is)
BG (1) BG64390B1 (is)
BR (1) BRPI9809126B8 (is)
CA (1) CA2289753C (is)
CO (1) CO4940435A1 (is)
DE (1) DE69821758T2 (is)
DK (1) DK0983271T3 (is)
DZ (1) DZ2493A1 (is)
EA (1) EA001809B1 (is)
EE (1) EE03924B1 (is)
EG (1) EG23836A (is)
ES (1) ES2214712T3 (is)
GB (3) GB9709945D0 (is)
GE (1) GEP20022680B (is)
HK (1) HK1024236A1 (is)
HN (1) HN1998000071A (is)
HR (1) HRP980265B1 (is)
HU (1) HU226563B1 (is)
ID (1) ID24910A (is)
IL (2) IL132793A0 (is)
IS (1) IS2207B (is)
JO (1) JO2032B1 (is)
MA (1) MA26498A1 (is)
MY (1) MY120151A (is)
NO (1) NO324731B1 (is)
NZ (2) NZ500865A (is)
OA (1) OA11304A (is)
PA (1) PA8451301A1 (is)
PE (1) PE78799A1 (is)
PL (1) PL189527B1 (is)
PT (1) PT983271E (is)
RS (1) RS49655B (is)
SA (1) SA98190179B1 (is)
SI (1) SI0983271T1 (is)
SK (1) SK285159B6 (is)
SV (1) SV1998000057A (is)
TN (1) TNSN98065A1 (is)
TR (1) TR199902810T2 (is)
TW (1) TW480259B (is)
UA (1) UA56231C2 (is)
UY (1) UY25004A1 (is)
WO (1) WO1998052949A1 (is)
ZA (2) ZA984085B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1905772A1 (en) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
AU2007301934A1 (en) * 2006-09-28 2008-04-03 Esteve Quimica, S.A. Process for the preparation of abacavir
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2305680A3 (en) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
ES2729824T3 (es) 2011-04-08 2019-11-06 Laurus Labs Ltd Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
ATE230267T1 (de) * 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv

Also Published As

Publication number Publication date
NO324731B1 (no) 2007-12-03
IL132793A0 (en) 2001-03-19
EA001809B1 (ru) 2001-08-27
TNSN98065A1 (fr) 2005-03-15
GB0010222D0 (en) 2000-06-14
GB9926839D0 (en) 2000-01-12
GB2348202A (en) 2000-09-27
EE9900537A (et) 2000-06-15
NZ510622A (en) 2002-04-26
IL132793A (en) 2006-10-31
HUP0002754A2 (hu) 2001-06-28
NZ500865A (en) 2001-04-27
YU59599A (is) 2002-08-12
KR20010012623A (ko) 2001-02-26
SA98190179B1 (ar) 2006-08-15
TW480259B (en) 2002-03-21
DZ2493A1 (fr) 2004-06-20
PE78799A1 (es) 1999-08-31
EA199900944A1 (ru) 2000-06-26
UA56231C2 (uk) 2003-05-15
SK156199A3 (en) 2000-07-11
PA8451301A1 (es) 2000-05-24
KR100521292B1 (ko) 2005-10-17
ZA984083B (en) 1999-11-15
AR015668A1 (es) 2001-05-16
SK285159B6 (sk) 2006-07-07
AP9901688A0 (en) 1999-12-31
MA26498A1 (fr) 2004-12-20
HRP980265A2 (en) 1999-02-28
AU7765598A (en) 1998-12-11
DE69821758D1 (de) 2004-03-25
CA2289753A1 (en) 1998-11-26
BR9809126A (pt) 2000-08-01
AR059120A2 (es) 2008-03-12
AU739953B2 (en) 2001-10-25
GEP20022680B (en) 2002-04-25
WO1998052949A1 (en) 1998-11-26
ID24910A (id) 2000-08-31
ES2214712T3 (es) 2004-09-16
GB2340491A (en) 2000-02-23
HK1024236A1 (en) 2000-10-05
TR199902810T2 (xx) 2000-02-21
JP3150711B2 (ja) 2001-03-26
ZA984085B (en) 2000-01-26
CN1515572A (zh) 2004-07-28
DK0983271T3 (da) 2004-05-10
SV1998000057A (es) 1999-03-02
BG64390B1 (bg) 2004-12-30
BRPI9809126B8 (pt) 2021-07-06
AP2009A (en) 2009-06-26
EE03924B1 (et) 2002-12-16
HU226563B1 (en) 2009-04-28
BG103959A (en) 2000-12-29
NO995622D0 (no) 1999-11-16
GB2340491B (en) 2000-10-18
NO995622L (no) 2000-01-14
SI0983271T1 (en) 2004-06-30
PT983271E (pt) 2004-07-30
RS49655B (sr) 2007-09-21
CN100408580C (zh) 2008-08-06
JP2000514096A (ja) 2000-10-24
HUP0002754A3 (en) 2003-01-28
IS2207B (is) 2007-02-15
MY120151A (en) 2005-09-30
ATE259811T1 (de) 2004-03-15
JP2000327679A (ja) 2000-11-28
PL189527B1 (pl) 2005-08-31
PL336888A1 (en) 2000-07-17
HN1998000071A (es) 1999-03-19
JO2032B1 (en) 1999-05-15
CA2289753C (en) 2007-01-23
CO4940435A1 (es) 2000-07-24
US6294540B1 (en) 2001-09-25
OA11304A (en) 2003-10-22
EG23836A (en) 2007-10-02
HRP980265B1 (en) 2004-10-31
EP0983271B1 (en) 2004-02-18
GB2348202B (en) 2001-08-08
DE69821758T2 (de) 2005-01-13
BRPI9809126B1 (pt) 2018-02-06
UY25004A1 (es) 2000-10-31
CN1150194C (zh) 2004-05-19
EP0983271A1 (en) 2000-03-08
GB9709945D0 (en) 1997-07-09
CN1263529A (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
NO972983D0 (no) Sulfonamider og deres anvendelse
NO964958D0 (no) Aluminium-scandiumlegeringer og deres anvendelse
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK0905016T3 (da) Skumfender og båd omfattende samme
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
NO973338D0 (no) N-(4-aryl-tiazol-2-yl)-sulfonamid-derivater og deres anvendelse
NO971811D0 (no) Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler
IS5246A (is) Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum
NO983576D0 (no) Brönnbehandlingsfluider og fremgangsmåter
IS2126B (is) Bætt hönnun á hólfi vörpukerfis og aðferðir
NO995513L (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-
DK4491D0 (da) Aclonifen-baserede herbicidblandinger og deres anvendelse
IS5713A (is) Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
DE69510034D1 (de) Trennbare und wiederanschliessbare verbindungsvorrichtung
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
IS1813B (is) Notkun á ferróseni og/eða ferrósenafleiðum
NO983332D0 (no) Gassboblesuspensjoner og deres anvendelse som ultralydkontrastmiddel
NO970165D0 (no) Kortikotropin frigivningsfaktor-bindingsprotein inhibitorer og deres anvendelse
KR950028146U (ko) 기포식 냉각 및 살균장치